Rx Product News (September 2014)
Marketed by: Teva Respiratory, LLC
Indication: The FDA has approved
QVAR (beclomethasone dipropionate HFA) for the maintenance treatment of asthma as prophylactic therapy in patients 5 years and older. QVAR is also indicated for asthma patients who require systemic corticosteroid administration, when adding QVAR may reduce or eliminate the need for systemic corticosteroids. For the recommended dosing of QVAR and the directions for use, see the full prescribing information.
Dosage Form: Inhalation aerosol: 40 and 80 mcg
For More Information: http://qvar.com
Marketed by: AstraZeneca
Indication: The FDA has approved Epanova (omega-3-carboxylic acids) as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia (≥500 mg/dL). The recommended dosage is 2 g or 4 g once daily. Therapy should be individualized according to patient response and tolerability. The capsules should be swallowed whole.
Dosage Form: Soft gelatin capsules: 1 g
For More Information: www.epanovahcp.com
Marketed by: Merck & Co, Inc
Indication: The FDA has approved Zontivity (vorapaxar), a proteaseactivated receptor—1 antagonist, for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction or with peripheral arterial disease. The recommended dosage is 1 tablet orally once daily. Use with aspirin and/or clopidogrel should be according to their indications or standard of care.
Dosage Form: Tablets: 2.08 mg
For More Information: www.zontivity.com
Marketed by: Greer Laboratories, Inc
Indication: The FDA has approved Oralair, an allergen extract, as immunotherapy for grass pollen—induced allergic rhinitis with or without conjunctivitis, as confirmed by positive skin test or in vitro testing for pollenspecific IgE antibodies for any of the 5 grass species contained in Oralair. For the recommended dosing, see the full prescribing information.
Dosage Form: Tablets: 100 and 300 IR (index of reactivity)
For More Information: http://oralair.com